1. UNAIDS Report on Global AIDS Epidemic 2013. Available at: http://www.unaids.org/globalreport/Global_report_2013_en_pdf [accessed Dec 16, 2015]. | | 2. Cesar C, Shepherd BE, Krollewiecki AJ, Fink VI, Schechter M, Tuboi SH, et al. Rates and reasons for early change of first HAART in HIV-1-infected in 7 sites throughout the Caribbean and Latin America. PLoS One. 2010;5(1):10490. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] | | 3. Fangel SJ. The effectiveness of highly active antiretroviral therapy in HIV-infected patients. Dan Med Bull. 2004;51:371-92. | | 4. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV cohort study. Lancet. 2001;358(9290):1322-7. [DOI via Crossref] | | 5. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45. [DOI via Crossref] [Pubmed] | | 6. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49:2229-32. [Pubmed] | | 7. Rawlins MD, Thompson JW. Mechanism of adverse drug reaction. In: Davies DM (Ed.), Textbook of Adverse Drug Reactions, 4th edn. Oxford: Oxford Medical Publication, 1991. | | 8. Srikanth BA, Babu SC, Yadav HN, Jain SK. Incidence of adverse drug reactions in human immune deficiency virus-positive patients using highly active antiretroviral therapy. J Adv Pharm Technol Res. 2012;3(1):62-7. [Pubmed] [PMC Free Fulltext] | | 9. Lartey M, Quashie AA, Essel A, Kenu E, Ganu V, Neequaye A. Adverse drug reactions to antiretroviral therapy during the early art period at a tertiary hospital in Ghana. Pan Afr Med J. 2014;18:25. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] | | 10. Jha AK, Gadgade A, Shenoy AK, Chowta MN, Ramapuram JT. Evaluation of adverse drug reaction in HIV positive patients in a tertiary care hospital. Perspect Clin Res. 2015;6(1):34-6. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] | | 11. Maniar NG, Desai S. Antiretroviral therapy: real challenges for developing world. AIDS. 2000;14(4):86. | | 12. Millogo A, Lankoande D, Yameogo I, Yaméogo AA, Sawadogo AB. Polyneuropathies in patients treated with HAART in BoboDioulasso hospital, Burkina Faso. Bull Soc Pathol Exot. 2008; 101:11-3. [Pubmed] | | 13. Montessori V, Press N, Harris M, Akagi L, Montaner JSG. Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004; 170(2). [Pubmed] [PMC Free Fulltext] | | 14. Nadkar MY, Bajpai S. Antiretroviral therapy: toxicity and adherence. J Assoc Physicians India. 2009;57(5):375-6. [Pubmed] | | 15. Ogundahunsi OA, Oyegungle VA, Ogun SA, Odusoga OL, Daniel OJ. HAART and lipid metabolism in a resource poor West African setting. Afr J Biomed Res. 2008;11:27-31. | | 16. Patel AK, Pujari S, Patel K, Patel J, Shah N, Patel B, et al. Nevirapine versus efavirenz based antiretroviral treatment in naïve Indian patients: comparison of effectiveness in clinical cohort. JAPI. 2006;54:915-8. [Pubmed] | | 17. Salami AK, Olatunji PO, Fawibe EA, Oluboyo PO. Influence of highly active antiretroviral therapy (HAART) on the survival of HIVinfected patients: part report of the ilorin trial centre. Afr J Clin Experimen Microbiol. 2005;6:34-9. | | 18. Sharma A, Vora R, Modi M, Sharma A, Marfati Y. Adverse effects of antiretroviral treatment. Indian J Dermatol Venereol Leprol. 2008;74(3):234-7. [DOI via Crossref] [Pubmed] | | 19. Singh H, Dulhani N, Tiwari P, Singh P, Sinha T. A prospective, observational cohort study to elicit adverse effects of antiretroviral agents in a remote resource-restricted tribal population of Chhattisgarh. Indian J Pharmacol. 2009;41(5):224-6. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] | | 20. Seth P. The situation of HIV/M.tuberculosis co-infection in India. Open Infect Dis J. 2011;5(1-5):51-9. [DOI via Crossref] | | 21. Heil EL, Townsend ML, Shipp K, Clarke A, Johnson MD. Incidence of severe hepatotoxicity related to antiretroviral therapy in HIV/HCV coinfected patients. AIDS Res Treat 2010; article ID 856542. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] | | 22. Reliquet V, Mussini JM, Chennebault JM, Lafeuillade A, Raffi F. Peripheral neuropathy during Stavudine-Didanosine antiretroviral therapy. HIV Med. 2001;2(2):92-6. [DOI via Crossref] [Pubmed] | | 23. Radhakrishnan R, Vidyasagar S, Varma M, Naik A, Hegde MB, Guddattu V, Kamath A. Pattern of use of highly active antiretroviral therapy regimens and pattern of occurrence of adverse drug reactions in an Indian human immunodeficiency virus positive patients. Clin Res HIV Aids Prevention. 2013;1(3):1-12. | | 24. Reddy AVK, Lihite RJ, Lahkar M, Choudhury U, Baruah SK. A study on adverse drug reactions in HIV infected patients at a art centre of tertiary care hospital in Guwahati, India. Asian J Pharm Clin Res. 2013;6(2):102-4. | |
|
|